immunostimulant

Bropirimine (U-54461) (U-54461) is a biological response modifier that is thought to act through the induction of lymphokines.

IPN60090 is a novel, potent, orally bioavailable, renal-type glutaminase (GLS1)-specific inhibitor with an IC50 value of 31 nM for GLS1. IPN60090 has potential anticancer and immunostimulant immunomodulatory activity, selectively targets, binds, and inhibits human glutaminase, and can be used to study GLS1-mediated diseases.

Quadrol (EDTP) is an immunostimulant, accelerated wound healing.

N-Methylsarcosine (Dimethylglycine) is used as an athletic performance enhancer and immunostimulant. It is also used in the treatment of autism, epilepsy and mitochondrial disease. It is also employed as a biomarker of protein degradation in chronic obstructive lung disease (COPD) patients. Further, it is used as a substrate to identify, differentiate and characterize amino acid methyltransferase. It plays an important role in the development of glycine-based ionic liquids and emulsifiers.

L-Allothreonine (L-allo-Threonine) is an essential amino acid in humans. L-Allothreonine is abundant in human plasma, particularly in newborns. Severe deficiency of threonine causes neurological dysfunction and lameness in experimental animals. L-Allothreonine is an immunostimulant which promotes the growth of thymus gland. L-Allothreonine also can probably promote cell immune defense function. L-Allothreonine is highly concentrated in meat products, cottage cheese, and wheat germ.

Loxoribine (RWJ 21757) is a guanosine analog. Loxoribine is an orally bioavailable and selective Toll-like receptor (TLR) 7 agonist. It has anti-viral and anti-tumor activities.Loxoribine is a potent new immunostimulant with a relatively broad spectrum of immunobiological activities.

TLR7 agonist27 (compound 24) is an effective TLR7 agonist with an EC50 of 238.1 nM. It exhibits weak agonistic activity towards NOD2 (nucleotide-binding oligomerization domain 2) with an EC50 of 6.2 μM. TLR7 agonist27 serves as a potent immunostimulant and can be utilized as a vaccine adjuvant and or an immunotherapeutic agent.

LH 1 is an immunostimulant used in antitumor treatment.

Roquinimex (FCF89) (Linomide) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha.

ODN 1826 is a 20-mer DNA strand, a TLR9 agonist and an immunostimulant, with anti-tumor and cardioprotective effects, promoting apoptosis, and stimulating the production of NO and iNOS. ODN 1826 is a CpG DNA mimetic that can be used as an adjuvant for synthetic vaccines.

Sovipostobart, an immunoglobulin G1-kappa monoclonal antibody targeting CTLA-4 in Homo sapiens, features a cleavable prodomain. This compound serves as both an immunostimulant and antineoplastic [1].

Rolistobart is a humanized IgG4-κ monoclonal antibody targeting LILRB4/CD85k. It functions as an immunostimulant and antineoplastic agent [1].

Perenostobart is a humanized IgG4-κ monoclonal antibody designed to target the ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1/CD39) protein, an enzyme expressed on immunosuppressive cells within the tumor microenvironment, thereby conferring the antibody with dual immunostimulatory and direct antineoplastic properties for oncology applications.

Muzastotug is a humanized IgG1-kappa monoclonal antibody targeting CTLA4, functioning as an immunostimulant and antineoplastic [1].

Lipustobart is an IgG4-kappa humanized monoclonal antibody targeting PDCD1 (programmed cell death 1, PD1, PD-1, CD279), with immunostimulant and antineoplastic activity [1].

Enlonstobart is a humanized IgG4-κ monoclonal antibody targeting PDCD1, functioning as both an immunostimulant and antineoplastic agent [1].

Danburstotug (IMC-001), an immunostimulant and antineoplastic [1], is a humanized IgG1-lambda monoclonal antibody targeting CD274 (PDL1, B7 homologue 1, B7H1).

Abazistobart is an immunostimulant and antitumor agent targeting programmed cell death protein 1 (PDCD1). This chimeric humanized monoclonal antibody specifically binds to PDCD1, blocking associated signaling pathways, thereby activating the immune system to exert antitumor effects. Abazistobart holds promise for cancer research applications.